Market Closed -
Japan Exchange
02:00:00 2024-05-20 am EDT
|
5-day change
|
1st Jan Change
|
240
JPY
|
+0.42%
|
|
+0.42%
|
+27.66%
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,673
|
-
|
-
|
Enterprise Value (EV)
1 |
9,673
|
9,673
|
9,673
|
P/E ratio
|
-110
x
|
-7.5
x
|
-7.5
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.8
x
|
-
|
-
|
EV / Revenue
|
13.8
x
|
-
|
-
|
EV / EBITDA
|
-10.2
x
|
-7.65
x
|
-7.5
x
|
EV / FCF
|
-114
x
|
-10.7
x
|
-7.44
x
|
FCF Yield
|
-0.88%
|
-9.3%
|
-13.4%
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,304
|
-
|
-
|
Reference price
2 |
240.0
|
240.0
|
240.0
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net sales
1 |
700
|
-
|
-
|
EBITDA
1 |
-950
|
-1,265
|
-1,290
|
EBIT
1 |
-85.1
|
-1,275
|
-1,300
|
Operating Margin
|
-12.16%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-79
|
-1,275
|
-1,300
|
Net income
1 |
-80
|
-1,275
|
-1,300
|
Net margin
|
-11.43%
|
-
|
-
|
EPS
2 |
-2.190
|
-32.00
|
-32.00
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
FCF margin
|
-12.13%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024 Q4
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
13.23
|
Dividend per Share
|
-
|
Announcement Date
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
1 |
10
|
10
|
10
|
Capex / Sales
|
1.43%
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Average target price
760
JPY Spread / Average Target +216.67% Consensus |
1st Jan change
|
Capi.
|
---|
| +27.66% | 61.97M | | +41.79% | 50.93B | | -0.56% | 42.12B | | +49.62% | 42.05B | | -7.20% | 29.18B | | +12.59% | 26.02B | | -21.51% | 18.9B | | +6.92% | 13.21B | | +24.91% | 12.17B | | +29.60% | 12.16B |
Other Biotechnology & Medical Research
|